Table 3.

Self-reported incidence of practical issues in VKA and NOAC users

		VKA (n = 389)	NOAC (n = 376)	p-value
Patients reporting practical issues				<0.001
	Common	63 (16.2%)	14 (3.7%)
	Occasional	16 (4.1%)	5 (1.3%)
Size and shape of drug				0.001
	Common	31 (8%)	9 (2.4%)
	Occasional	5 (1.3%)	1 (0.3%)
Level of hindrance
	Moderate	9(26.5%)	2 (22.2%)
	Serious	12 (35.3%)	2 (22.2%)
	Severe	12 (35.3%)	5 (55.6%)
Intake issues				0.14
	Common	10 (2.6%)	3 (0.8%)
	Occasional	2 (0.5%)	1 (0.3%)
Level of hindrance
	Moderate	5 (45.5%)	2 (66.7%)
	Serious	3 (27.3%)	1 (33.3%)
	Severe	3 (27.3%)	0
Dose adjustment according to scheme				<0.001
	Common	32 (8.2%)	4 (1.1%)
	Occasional	10 (2.6%)	3 (0.8%)
Level of hindrance
	Moderate	19 (45.2%)	3 (42.9%)
	Serious	7 (16.7%)	1 (14.3%)
	Severe	7 (16.7%)	2 (28.6%)

Complete questions (in Dutch) available in the Electronic Supplementary Material, Appendix 1

VKA vitamin‑K antagonist, NOAC non-vitamin‑K oral anticoagulant